Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 41 results.
User Information
Export Records
  1. 1.   Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma
  2. Huang, Chen; Chen, Lijun; Savage, Sara R.; Eguez, Rodrigo Vargas; Dou, Yongchao; Li, Yize; Leprevost, Felipe da Veiga; Jaehnig, Eric J.; Lei, Jonathan T.; Wen, Bo; Schnaubelt, Michael; Krug, Karsten; Song, Xiaoyu; Cieslik, Marcin; Chang, Hui-Yin; Wyczalkowski, Matthew A.; Li, Kai; Colaprico, Antonio; Li, Qing Kay; Clark, David J.; Hu, Yingwei; Cao, Liwei; Pan, Jianbo; Wang, Yuefan; Cho, Kyung-Cho; Shi, Zhiao; Liao, Yuxing; Jiang, Wen; Anurag, Meenakshi; Ji, Jiayi; Yoo, Seungyeul; Zhou, Daniel Cui; Liang, Wen-Wei; Wendl, Michael; Vats, Pankaj; Carr, Steven A.; Mani, D. R.; Zhang, Zhen; Qian, Jiang; Chen, Xi S.; Pico, Alexander R.; Wang, Pei; Chinnaiyan, Arul M.; Ketchum, Karen A.; Kinsinger, Christopher R.; Robles, Ana; An, Eunkyung; Hiltke, Tara; Mesri, Mehdi; Thiagarajan,Mathangi; Weaver, Alissa M.; Sikora, Andrew G.; Lubinski, Jan; Wierzbicka, Malgorzata; Wiznerowicz, Maciej; Satpathy, Shankha; Gillette, Michael A.; Miles, George; Ellis, Matthew J.; Omenn, Gilbert S.; Rodriguez, Henry; Boja, Emily S.; Dhanasekaran, Saravana M.; Ding, Li; Nesvizhskii, Alexey; El-Naggar, Adel K.; Chan, Daniel W.; Zhang, Hui; Zhang, Bing
  3. Cancer Cell. 2021, Mar 8; 39(3): 361-379.
  1. 2.   Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts
  2. Woo, Xing Yi; Giordano, Jessica; Srivastava, Anuj; Zhao, Zi-Ming; Lloyd, Michael W.; de Bruijn, Roebi; Suh, Yun-Suhk; Patidar, Rajesh; Chen,Li; Scherer, Sandra; Bailey, Matthew H.; Yang, Chieh-Hsiang; Cortes-Sanchez, Emilio; Xi, Yuanxin; Wang, Jing; Wickramasinghe, Jayamanna; Kossenkov, Andrew V.; Rebecca, Vito W.; Sun, Hua; Mashl, R. Jay; Davies, Sherri R.; Jeon, Ryan; Frech, Christian; Randjelovic, Jelena; Rosains, Jacqueline; Galimi, Francesco; Bertotti, Andrea; Lafferty, Adam; O'Farrell, Alice C.; Modave, Elodie; Lambrechts, Diether; ter Brugge, Petra; Serra, Violeta; Marangoni, Elisabetta; El Botty, Rania; Kim, Hyunsoo; Kim, Jong-Il; Yang, Han-Kwang; Lee, Charles; Dean, Dennis A.; Davis-Dusenbery, Brandi; Evrard, Yvonne A.; Doroshow, James H.; Welm, Alana L.; Welm, Bryan E.; Lewis, Michael T.; Fang, Bingliang; Roth, Jack A.; Meric-Bernstam, Funda; Herlyn, Meenhard; Davies, Michael A.; Ding, Li; Li, Shunqiang; Govindan, Ramaswamy; Isella, Claudio; Moscow, Jeffrey A.; Trusolino, Livio; Byrne, Annette T.; Jonkers, Jos; Bult, Carol J.; Medico, Enzo; Chuang, Jeffrey H.
  3. Nature Genetics. 2021, Jan; 53(1): 86-99.
  1. 3.   Single cell-derived primary rectal carcinoma cell lines reflect intratumor heterogeneity associated with treatment response
  2. Braun, Rüdiger; Anthuber, Lena; Hirsch, Daniela; Wangsa, Darawalee; Lack,Justin; McNeil, Nicole E; Heselmeyer-Haddad, Kerstin; Torres, Irianna; Wangsa, Danny; Brown, Markus A; Tubbs, Anthony; Auslander, Noam; Gertz, E Michael; Brauer, Philip R; Cam,Maggie; Sackett, Dan; Habermann, Jens K; Nussenzweig, Andre; Ruppin, Eytan; Zhang, Zhongqiu; Rosenberg, Daniel W; Ried, Thomas
  3. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020, JUL; 26(13): 3468-3480.
  1. 4.   Systematic Establishment of Robustness and Standards in Patient-Derived Xenograft Experiments and Analysis
  2. Evrard,Yvonne; Srivastava, Anuj; Randjelovic, Jelena; Consortium, Nci PDXNet; Doroshow, James H; Dean, Dennis A; Morris, Jeffrey S; Chuang, Jeffrey H
  3. Cancer research. 2020, JUN 1; 80(11): 2286-2297.
  1. 5.   Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers
  2. Wilsker,Deborah; Barrett, Allison M.; Dull,Angie; Lawrence,Scott; Hollingshead,Melinda; Chen, Alice; Kummar, Shivaani; Parchment,Ralph; Doroshow, James H.; Kinders,Robert
  3. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019, MAY 15; 25(10): 3084-3095.
  1. 6.   Novel cancer gene variants and gene fusions of triple-negative breast cancers (TNBCs) reveal their molecular diversity conserved in the patient-derived xenograft (PDX) model
  2. Jung, Jaeyun; Jang, Kiwon; Ju, Jung Min; Lee, Eunji; Lee, Jong Won; Kim, Hee Jung; Kim, Jisun; Lee, Sae Byul; Ko, Beom Seok; Son, Byung Ho; Lee, Hee Jin; Gong, Gyungyup; Ahn, Sei Yeon; Choi, Jung Kyoon; Singh, Shree Ram; Chang, Suhwan
  3. Cancer Letters. 2018, Aug 01; 428: 127-138.
  1. 7.   Patterns of Sensitivity to a Panel of Drugs are highly Individualized for Undifferentiated/Unclassified Soft Tissue Sarcoma (USTS) in Patient-Derived Orthotopic Xenograft (PDOX) Nude-Mouse Models
  2. Kawaguchi, Kei; Igarashi, Kentaro; Miyake, Kentaro; Kiyuna, Tasuku; Miyake, Masuyo; Singh, Arun S; Chmielowski, Bartosz; Nelson, Scott D; Russell, Tara A; Dry, Sarah M; Li, Yunfeng; Unno, Michiaki; Singh, Shree Ram; Eilber, Fritz C; Hoffman, Robert M
  3. Journal of drug targeting. 2018, Jul 19; 1-25.
  1. 8.   Comparison of planar, PET and well-counter measurements of total tumor radioactivity in a mouse xenograft model.
  2. Green, Michael V; Seidel, Jurgen; Williams, Mark; Wong, Karen J; Ton, Anita; Basuli, Falguni; Choyke, Peter L; Jagoda, Elaine M
  3. Nuclear medicine and biology. 2017, Oct; 53: 29-36.
  1. 9.   Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay
  2. Ji, Jay; Zhang, Yiping; Redon, Christophe E.; Reinhold, William C.; Chen, Alice P.; Fogli, Laura K.; Holbeck, Susan L.; Parchment, Ralph; Hollingshead, Melinda; Tomaszewski, Joseph E.; Dudon, Quentin; Pommier, Yves; Doroshow, James H.; Bonner, William M.
  3. PLOS ONE. 2017, Feb 3; 12(2): e0171582.
  1. 10.   Cytotoxic Activity of Immunotoxin SS1P Is Modulated by TACE-Dependent Mesothelin Shedding
  2. Zhang, Y. J.; Chertov, O.; Zhang, J. L.; Hassan, R.; Pastan, I.
  3. Cancer Research. 2011, Sep; 71(17): 5915-5922.
  1. 11.   Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1 alpha in Advanced Solid Tumors
  2. Kummar, S.; Raffeld, M.; Juwara, L.; Horneffer, Y.; Strassberger, A.; Allen, D.; Steinberg, S. M.; Rapisarda, A.; Spencer, S. D.; Figg, W. D.; Chen, X. H.; Turkbey, I. B.; Choyke, P.; Murgo, A. J.; Doroshow, J. H.; Melillo, G.
  3. Clinical Cancer Research. 2011, Aug; 17(15): 5123-5131.
  1. 12.   Lymphoid-Specific Helicase (HELLS) Is Essential for Meiotic Progression in Mouse Spermatocytes
  2. Zeng, W. X.; Baumann, C.; Schmidtmann, A.; Honaramooz, A.; Tang, L.; Bondareva, A.; Dores, C.; Fan, T.; Xi, S. C.; Geiman, T.; Rathi, R.; de Rooij, D.; De La Fuente, R.; Muegge, K.; Dobrinski, I.
  3. Biology of Reproduction. 2011, Jun; 84(6): 1235-1241.
  1. 13.   Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
  2. Rapisarda, A.; Hollingshead, M.; Uranchimeg, B.; Bonomi, C. A.; Borgel, S. D.; Carter, J. P.; Gehrs, B.; Raffeld, M.; Kinders, R. J.; Parchment, R.; Anver, M. R.; Shoemaker, R. H.; Melillo, G.
  3. Molecular Cancer Therapeutics. 2009 8(7): 1867-1877.
  1. 14.   Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition
  2. Dang, D. T.; Chun, S. Y.; Burkitt, K.; Abe, M.; Chen, S.; Havre, P.; Mabjeesh, N. J.; Heath, E. I.; Vogelzang, N. J.; Cruz-Correa, M.; Blayney, D. W.; Ensminger, W. D.; Croix, B. S.; Dang, N. H.; Dang, L. H.
  3. Cancer Research. 2008 68(6): 1872-1880.
  1. 15.   PABA/NO as an anticancer lead: Analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity
  2. Saavedra, J. E.; Srinivasan, A.; Buzard, G. S.; Davies, K. M.; Waterhouse, D. J.; Inami, K.; Wilde, T. C.; Citro, M. L.; Cuellar, M.; Deschamps, J. R.; Parrish, D.; Shami, P. J.; Findlay, V. J.; Townsend, D. M.; Tew, K. D.; Singh, S.; Jia, L.; Ji, X. H.; Keefer, L. K.
  3. Journal of Medicinal Chemistry. 2006, FEB 9; 49(3): 1157-1164.
  1. 16.   Phase I trial of temozolomide plus O-6-benzylguanine for patients with recurrent or progressive malignant glioma
  2. Quinn, J. A.; Desjardins, A.; Weingart, J.; Brem, H.; Dolan, M. E.; Delaney, S. M.; Vredenburgh, J.; Rich, J.; Friedman, A. H.; Reardon, D. A.; Sampson, J. H.; Pegg, A. E.; Moschel, R. C.; Birch, R.; McLendon, R. E.; Provenzale, J. M.; Gururangan, S.; Dancey, J. E.; Maxwell, J.; Tourt-Uhlig, S.; Herndon, J. E.; Bigner, D. D.; Friedman, H. S.
  3. Journal of Clinical Oncology. 2005, OCT 1; 23(28): 7178-7187.
  1. 17.   In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative
  2. Hollingshead, M.; Alley, M.; Burger, A. M.; Borgel, S.; Pacula-Cox, C.; Fiebig, H. H.; Sausville, E. A.
  3. Cancer Chemotherapy and Pharmacology. 2005, AUG; 56(2): 115-125.
  1. 18.   A new synthetic agent with potent but selective cytotoxic activity against cancer
  2. Cholody, W. M.; Kosakowska-Cholody, T.; Hollingshead, M. G.; Hariprakasha, H. K.; Michejda, C. J.
  3. Journal of Medicinal Chemistry. 2005, JUN 30; 48(13): 4474-4481.
  1. 19.   Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine
  2. Dote, H.; Cerna, D.; Burgan, W. E.; Carter, D. J.; Cerra, M. A.; Hollingshead, M. G.; Camphausen, K.; Tofilon, P. J.
  3. Clinical Cancer Research. 2005, JUN 15; 11(12): 4571-4579.
  1. 20.   Elucidation of thioredoxin as a molecular target for antitumor quinols
  2. Bradshaw, T. D.; Matthews, C. S.; Cookson, J.; Chew, E. H.; Shah, M.; Bailey, K.; Monks, A.; Harris, E.; Westwell, A. D.; Wells, G.; Laughton, C. A.; Stevens, M. F. G.
  3. Cancer Research. 2005, MAY 1; 65(9): 3911-3919.
  1. 21.   NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts
  2. Papadopoulou, M. V.; Bloomer, W. D.; Hollingshead, M. G.
  3. Anticancer Research. 2005, MAY-JUN; 25(3B): 1865-1869.
  1. 22.   Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele
  2. Graveel, C.; Su, Y. L.; Koeman, J.; Wang, L. M.; Tessarollo, L.; Fiscella, M.; Birchmeier, C.; Swiatek, P.; Bronson, R.; Woude, G. V.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2004, DEC 7; 101(49): 17198-17203.
  1. 23.   Enhanced tumor cell radiosensitivity and abrogation of G(2) and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
  2. Bull, E. E. A.; Dote, H.; Brady, K. J.; Burgan, W. E.; Carter, D. J.; Cerra, M. A.; Oswald, K. A.; Hollingshead, M. G.; Camphausen, K.; Tofilon, P. J.
  3. Clinical Cancer Research. 2004, DEC 1; 10(23): 8077-8084.
  1. 24.   Schedule-dependent inhibition of hypoxia-inducible factor-1 alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts
  2. Rapisarda, A.; Zalek, J.; Hollingshead, M.; Braunschweig, T.; Uranchimeg, B.; Bonomi, C. A.; Borgel, S. D.; Carter, J. P.; Hewitt, S. M.; Shoemaker, R. H.; Melillo, G.
  3. Cancer Research. 2004, OCT 1; 64(19): 6845-6848.
  1. 25.   SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 2: Efficacy evaluations
  2. Alley, M. C.; Hollingshead, M. G.; Pacula-Cox, C. M.; W, W. R.; Hartley, J. A.; Howard, P. W.; Gregson, S. J.; Thurston, D. E.; Sausville, E. A.
  3. Cancer Research. 2004, SEP 15; 64(18): 6700-6706.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel